SEC Form 4 · accession 0001743658-26-000002
Xeris Biopharma Holdings, Inc. · XERS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Dawn Halkuff
Director
Period of report
Jun 4, 2026
Accepted (ET)
Jun 5, 2026 · 6:18 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001867096
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Jun 4, 2026 | S | 20,000 | $6.0943 | D | 95,000 | D | |
| Common StockF3 | Jun 4, 2026 | A | 24,193 | $0.00 | A | 119,193 | D | |
| Common StockF4 | holding | — | — | — | 5,410 | I | By; DAWN HALKUFF REVOCABLE TRUST U/A DTD 08/25/2017 |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F5 | $6.15 | Jun 4, 2026 | A | 32,996 | A | — | Jun 4, 2036 | Common Stock | 32,996 | 32,996 | D |
Explanation of responses
- F1The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 4, 2025.
- F2The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.960 to $6.170, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- F3These shares were acquired pursuant to a restricted stock unit grant under the Company's 2018 Stock Option and Incentive Plan (the "Plan"). Each restricted stock represents a contingent right to receive one share of the Company's common stock. These shares shall vest in full upon the earlier to occur of June 4, 2026 or the date of the Company's next annual meeting of stockholders, subject to continued service through such vesting date.
- F4The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
- F5These stock options were acquired pursuant to a grant under the Plan. These stock options shall vest in full upon the earlier to occur of June 4, 2026 or the date of the Company's next annual meeting of stockholders, subject to continued service through such vesting date.